First-Ever EBV vaccine trial seeks to stop 'Mono' virus that causes fatigue and cancer risk
NCT ID NCT05683834
Summary
This early-stage clinical trial is testing a new vaccine designed to prevent infection with Epstein-Barr virus (EBV), which causes mononucleosis ('mono') and is linked to certain cancers. The study involves healthy young adults aged 18-25 who have never had EBV before. Participants receive either the experimental vaccine or a placebo injection to compare safety and immune response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPSTEIN-BARR VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.